Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-11-30
1997-03-11
Nucker, Christine M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 514 13, 514 14, 514 16, 514 17, 514 18, 530324, 530326, 530327, 530328, 530329, 530330, A61K 3800
Patent
active
056101414
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to the use of peptides having a stimulating effect on cell proliferation, and to novel peptides having specific and/or general cell stimulating effects.
The mammalian body contains cells having enormously diverse structures and functions, and the mechanisms of differentiation and development have been the focus of much study. It is known that for systems of cells having a continuous turnover the mechanism commonly involves a reservoir of pluripotent stem cells which divide and constantly supply new cells to the system. While initially homogeneous the stem cells supplied from the "reservoir" soon become committed to one or other morphology and subsequently develop into the required functional cells.
Examples of such stem cell systems are the haemopoietic system in bone marrow and the epithelial and epidermal systems.
The manipulation or control of stem cell division is of great potential therapeutically and much research continues to be devoted to elucidating the mechanisms involved and the chemical messengers responsible. To date several biomolecules have been identified as possessing a role in cell production and differentiation either by the stimulation or inhibition of a step within the process. Myelopoiesis has been particularly well studied in this regard and molecules involved in its control include: colony-stimulating factors (CSF) such as granulocyte colony-stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), multi-lineage colony-stimulating factor (multi-CSF; IL-3) [see Metcalf, Science 229: 16 (1985)], interleukin 11 (IL-11) [see Paul et al Proc Natl Acad Sci USA 87: 7521 (1990)], Lactoferrin [see Broxmeyer et al Blood Cells 11: 429 (1986)], prostoglandins [see Pelus et al J. Immunol 140: 479 (1988)], acidic (H-subunit) ferritin [see Broxmeyer et al Blood 68: 1257 (1986)], interferons (.alpha., .beta. and .gamma.) [see Pelus et al supra. and Broxmeyer et al J. Immunol 131: 1300 (1983)], tumour necosis factors (.alpha. and .beta.) [see Broxmeyer et al J Immunol 136: 4487 (1986)], transforming growth factor-.beta. [see Ottman et al J Immunol 140: 2661 (1988)], and activin and inhibin [see Broxmeyer et al Proc Natl Acad Sci USA 86: 779 (1989)].
It has also been found that the haemoregulatory pentapeptide (pEEDCK) inhibits the proliferation of myelopoietic cells selectively [see Paukovits et al Z. Naturforsch 37: 1297 (1982)] and other peptides corresponding to a narrow general formula were discovered to exert a similar inhibitory effect in hemopoiesis [see EP-A-112656 and WO90/02753]. Oxidation of the peptide monomers resulted in dimeric molecules linked by a cysteine bridge and these dimeric molecules were found to stimulate myelopoiesis [see Laerum et al. Exp. Hematol 16: 274 (1988)]. The (pEEDCK).sub.2 dimer and other similar compounds are disclosed in WO-A-88/03535. Further dimeric peptide compounds are disclosed in EP-A-408371 in which the disulphide bond has been replaced by a carbon or carbon/sulphur bridge linking the selected peptide chains. The bridge is thus relatively stable to hydrolysis but is itself inert and incapable of participating in receptor-dimer interactions.
Whilst we do not wish to be bound by theoretical considerations, it is presently believed that such peptide compounds interact with stromal cells in vivo and that the stromal cells are responsible for stimulating or inhibiting cellular division via other soluble factors. The dimers are thus believed to induce or promote stromatic production of stimulatory cellular regulatory factor(s) whilst the monomeric peptides may either inhibit that process or cause the production of factors which prevent or hinder cell division. Thus, according to current thinking, the stromal cells may act to amplify the stimulatory or inhibitory effects of the dimeric and monomeric peptides respectively.
There is a continuing need for dimeric peptide compounds capable of stimulating cell proliferation to a useful level in vivo. In this reg
REFERENCES:
patent: 4058512 (1977-11-01), Sievertsson et al.
Bold et al., Helvetica Chimica Acta, vol. 75, No. 3, 6 May 1992, Basel, Switzerland, 865-882.
Merck Manual, Fifteenth Ed., Merck & Co., Rahway, NJ (1987). see pp. 1120-1121.
Agner Erik
Kremminger Peter
Lange Meinolf
Solbakken Magne
Undheim Kjell
Nucker Christine M.
Nycomed Imaging AS
Prickril Benet
LandOfFree
Double chain peptide compounds having hemoregulatory activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Double chain peptide compounds having hemoregulatory activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Double chain peptide compounds having hemoregulatory activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-443589